No-alpha IL-2 Mutein

About SarcoMed USA

SarcoMed USA is a private, preclinical-stage biotech company targeting significant unmet needs in pulmonary inflammation, primarily pulmonary sarcoidosis. Its core strategy involves repurposing or licensing inhaled DNase 1 enzyme therapy (SM001) to break down pro-inflammatory extracellular DNA complexes implicated in granuloma formation. The company has completed a Pre-IND meeting with the FDA, secured orphan designation, and is exploring additional indications like ARDS and IPF, while also holding an option on an immuno-oncology asset. It appears to be pre-revenue and is advancing toward clinical trials.

Therapeutic Areas

Other Cancer Drugs